First-Class Support

ELIGARD® offers comprehensive support and resources for your practice

mixingMIXING AND ADMINISTRATION SUPPORT >

Live in-services by Account Representative


Virtual demonstrations


Weekly webinars by Medical Affairs

mixingPATIENT EDUCATION MATERIALS >

When your patients have questions about their ADT, we have the resources to helpanswer them

mixingPRODUCT AND CLINICAL EDUCATION >

Full offering of clinical and product materials to help support you and your practice


HCPs

CUSTOMIZED PEER-TO-PEER HEALTHCARE PROFESSIONAL EDUCATION PROGRAMS

Virtual and in-person lectures for physicians, advanced practitioners, residents/fellows, nurses, and PharmDs. Contact your local Tolmar Account Manager or send an email to events@tolmar.com.

SEND AN EMAIL >

Resources to help your team

Whatever your role, all the information you need to prescribe, inject and manage ELIGARD can be found right here.

VISIT INFORMATION CENTER >

See details on mixing and administering ELIGARD

LEARN MORE >
DEPENDABLE PATIENT SUPPORT

Our commitment
to patient access

Tolmar Total Solutions is a comprehensive suite of reimbursement and patient assistance services dedicated to optimizing patient access to ELIGARD.

We offer a full line of patient support services, including:

  • Benefit verification
  • Assistance with prior authorizations, appeals, and billing and coding inquiries
  • Patient education materials
  • Patient Assistance Program

We support patient organizations, national and local professional associations, and patient advocacy groups

  • American Urological Association (AUA)
  • Large Urology Group Practice Association (LUGPA)
  • American Society of Clinical Oncology (ASCO)
  • Society of Urologic Oncology (SUO)
  • Society of Urologic Nurses and Associates (SUNA)
  • ZERO – The End of Prostate Cancer
  • Veterans Prostate Cancer Awareness (VPCa)

Access helpful ELIGARD patient resources

LEARN MORE >
Tap for safety information

IMPORTANT SAFETY INFORMATION

ELIGARD®, (leuprolide acetate) for injectable suspension, is indicated for the palliative treatment of advanced prostate cancer.

ELIGARD is contraindicated in patients with hypersensitivity to GnRH, GnRH agonists, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonists have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression. Monitor patients at risk closely and manage as appropriate.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH agonists in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported. See package insert for full Prescribing and Safety Information.

Please see full Prescribing Information for ELIGARD.